Navigation Links
Former FDA Commissioner Joins Bexion Pharmaceuticals Board
Date:1/6/2011

COVINGTON, Ky., Jan. 6, 2011 /PRNewswire/ -- Bexion Pharmaceuticals, LLC announced today that it has added Lester Crawford, D.V.M., and Ph.D. to its Board of Directors.

Dr. Crawford has had a distinguished career in the public and private sectors as well as academia. Over ten years of his career were spent at the Food and Drug Administration (FDA) serving in a variety of pivotal roles and culminating in his appointment as FDA Commissioner.

Prior to FDA, Dr. Crawford served in many capacities at the University of Georgia, including chair of the Department of Physiology and Pharmacology and at Georgetown University where he was director of the Center for Food and Nutrition Policy. Dr. Crawford has been an expert advisor to the World Health Organization, the Singapore FDA and the U. S. Academy of Sciences. He is currently a Partner and Senior Science Advisor at Policy Directions, Inc.

"We are excited and privileged to have Dr. Crawford join our Board of Directors," stated Dr. Ray Takigiku, Bexion's co-founder and CEO. "Dr. Crawford brings us important insights on regulatory and industry issues that are vital as we approach an IND submission in 2011, and anticipated clinical trials", added Dr. Takigiku.

"I am especially pleased to join Bexion's Board of Directors," added Dr. Crawford. "I am looking forward to sharing my experience over a long career to help Bexion reach its goal of providing first-in-class, innovative technology to cancer patients worldwide."

About Bexion Pharmaceuticals:Bexion Pharmaceuticals is focused on the development and commercialization of innovative cures for cancer.  Initial products are based on a proprietary platform technology licensed from Cincinnati Children's Hospital Medical Center.  The technology has demonstrated potential for development as therapeutic, diagnostic and surgical imaging reagents, and as carriers for other pharmaceutical agents, such as oligonucleotides.  For more information, visit www.bexionpharma.com.Bexion contact:Margaret M. van GilseVP, Investor RelationsBexion Pharmaceuticals, LLC632 Russell StreetCovington, KY 41011Phone: (513) 833-7065mvangilse@bexionpharma.com
'/>"/>

SOURCE Bexion Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
2. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
3. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
4. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
5. Michigan Life Science and Innovation Center Opens in Former Pfizer Facility
6. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
7. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
8. Former Miss USA Shawnae Jebbia Shines with Siemens Pure
9. Secure eHealth, LLC Engages as a Consultant GSI Health Whose Principal and CEO is the Former Senior Advisor to National Coordinator for Health Information Technology
10. Former Air Force Surgeon General Joins Integrated Medical Systems Advisory Board
11. SCAI Statement on the Hospitalization of Former President Bill Clinton
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... 2017  South Korean-based healthcare product Development Company I.M. ... on Kickstarter. The device will educate the user about ... better efficiency compared to the dated and pricey CPR ... efficacy of the compression for a more informed CPR ... to raise $5,000. ...
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... PurhealthRX , ... Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize ... providing a CBD form that can be easily incorporated into liquid products, while reducing ...
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and fastest ... to open a flagship location in Covington, LA at 401 N. U.S. Highway 190, ... next to Office Depot in the Holiday Square shopping center. Its location allows it ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):